What are the trends and outcomes of transcatheter aortic valve replacement (TAVR) in patients with myeloproliferative neoplasms compared to matched controls?

20 June 2026 (08:30 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Diagnosis and Management of Cardiovascular Disease in Patients with Cancer Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology